Zibac (Ceftazidime) is a third-generation cephalosporin antibiotic commonly used to address severe bacterial infections across several critical therapeutic domains. It is primarily prescribed for infections where the symptoms are caused by susceptible bacteria, and it is commonly used for conditions presenting with bacterial causes.

The medication is applicable in clinical settings that involve acute or unstable symptom patterns related to systemic infections, such as serious infections of the lungs (pneumonia), brain and spinal cord (meningitis), abdomen, and blood (septicemia). Its use is particularly relevant in contexts marked by increased discomfort or tension caused by difficult-to-treat bacteria, including Pseudomonas aeruginosa. This use may assist with managing symptoms that interfere with daily functioning in high-risk patient groups, such as those with febrile neutropenia or recurrent broncho-pulmonary infections in cystic fibrosis.

“Zibac supports patients during difficult episodes by easing distress and managing symptoms related to systemic imbalance.”

The primary benefit is that the use of Zibac is associated with addressing the bacterial source of the infection and assists with managing symptoms related to systemic imbalance, such as high fever and chills, which are part of the acute manifestations of systemic infection.

---

Quick Fact: Support for Systemic Imbalance

Zibac is commonly used to help with symptom clusters that may become intense or disruptive, and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Zibac?

Eligibility for Zibac (azithromycin) is strictly defined by regulatory documents, which establish absolute contraindications and specific population restrictions.

Contraindicated Populations

Zibac is contraindicated and must not be used in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide, or any ketolide antibacterial drug. It is also prohibited for patients with a history of cholestatic jaundice or hepatic dysfunction specifically associated with prior azithromycin use.

Eligibility Restrictions

Domain	Eligibility Status
Pediatric Age	Safety and effectiveness are not established for most indications in children under 6 months of age, or under 2 years of age for pharyngitis/tonsillitis.
Severe Illness	Use is not recommended for patients with pneumonia judged to be inappropriate for oral therapy due to moderate-to-severe illness or risk factors (e.g., known bacteremia, cystic fibrosis, or requiring hospitalization).
Renal Function	Caution is advised for patients with severe renal impairment (GFR <10 mL/min) due to increased systemic exposure.
Pregnancy/Lactation	Use during pregnancy is permitted only if clearly needed and the benefit is determined to outweigh the potential risk. Caution should be exercised when administered to a nursing woman as the drug is excreted in human milk.

Zibac (Ceftazidime) exhibits specific, formally documented interaction patterns primarily concerning pharmacodynamic effects and renal clearance, as defined in official regulatory documents.

Pharmacodynamic and Toxicity Interactions

Co-administration with Aminoglycosides (such as Gentamicin) carries an officially documented risk of increased nephrotoxicity and ototoxicity. This interaction is further constrained by a mandatory physical incompatibility: the two substances must not be mixed in the same solution for injection due to the risk of precipitation.

A pharmacodynamic antagonism has been observed in vitro with Chloramphenicol; this combination should be avoided when a full bactericidal outcome is desired. Additionally, the cephalosporin class is associated with a fall in prothrombin activity, which may increase the effect of Oral Anticoagulants.

Clearance and Population-Specific Notes

The drug is eliminated almost entirely by the kidneys, and this clearance mechanism defines several restrictions. Administration of Probenecid is documented to have no effect on Ceftazidime elimination kinetics, confirming that the drug is not actively secreted by renal tubular mechanisms. For patients with Renal Impairment, the drug's half-life is significantly prolonged, leading to excessive serum concentrations that increase the official risk of concentration-dependent neurologic adverse reactions. This population-specific finding is a key restriction noted in prescribing information. The medicine may also cause a false-positive reaction for glucose in the urine when using copper reduction methods.

Zibac, which contains the molecule azithromycin, operates primarily by inhibiting bacterial protein synthesis. The compound selectively targets the bacterial 50S ribosomal subunit.

It acts as a non-competitive inhibitor by binding to the 23S rRNA component of the 50S subunit, specifically at the nascent peptide exit tunnel. This binding event physically obstructs the tunnel and impedes the process of translocation, which is the movement of peptidyl-tRNA from the A-site to the P-site within the ribosome.

This molecular interaction causes a premature dissociation of the growing polypeptide chain, leading to the cellular consequence of an incomplete and non-functional proteome in the targeted microbial cell.

At the system level, the molecule exhibits extensive tissue distribution and significant intracellular accumulation, particularly within phagocytic cells (e.g., macrophages), which concentrates the compound at sites of microbial presence. The resulting cessation of protein production modulates the microbial population by inhibiting growth and replication.

Zibac is a cephalosporin antibiotic that requires administration by a healthcare professional, as its use is restricted to parenteral routes: specifically intravenous (IV) injection or infusion, and intramuscular (IM) deep injection. The medicine is supplied as a sterile dry powder that necessitates reconstitution with a sterile diluent (such as Water for Injection) prior to use. This preparation process requires venting the vial to relieve pressure created during dissolution, a critical procedural step.

Dosing and Frequency

The standard adult regimen typically involves a unit dose ranging from 500 mg up to 2 grams, administered on a scheduled basis, most commonly every 8 or 12 hours. For severe or life-threatening infections, the official maximum daily dose may reach 6 grams in patients with normal kidney function. This may be delivered via intermittent dosing or as a continuous 24-hour IV infusion, which is an officially approved schedule. Pediatric patient dosing is determined by weight (mg/kg), and older adults may receive reduced doses due to natural age-related changes in renal clearance.

Administration Requirements

A critical procedural instruction is the required dosage adjustment for any degree of renal impairment. Since the body eliminates the drug primarily through the kidneys, doses must be lowered and/or the time between administrations extended to align with the patient's measured Creatinine Clearance (CrCl). Treatment courses are generally maintained for 7 to 14 days, concluding only after the signs of infection have resolved.

Research Evidence / Overview of Studies for Zibac (Ceftazidime)

Zibac (Ceftazidime) has been evaluated through a body of clinical trials and comparative studies. The research primarily focuses on studies exploring its use in serious systemic bacterial infections, as research has explored.

---

Evidence for Use in Respiratory Tract and Systemic Infections

Research examined Zibac in the context of severe infections in the lungs, such as pneumonia acquired in a hospital setting, and other systemic infections that require immediate attention. These clinical evaluations generally involved Comparative Trials, where Zibac was evaluated in Comparative Trials, as well as analyses that summarized collective clinical experience.

In these studies, researchers monitored various endpoints, including the Clinical Cure/Success of the infection, which tracked the resolution or improvement of patient symptoms, and the rate of Microbiological Eradication, which monitored the reduction in or absence of the targeted susceptible bacteria. Study findings reported patterns observed related to these short-term clinical responses and were used in research contexts involving fluctuating or unstable symptoms.

---

Targeted Evidence Against Pseudomonas aeruginosa

A key area of research has explored Zibac's activity against Gram-negative bacteria, particularly the often difficult-to-treat organism, Pseudomonas aeruginosa. Studies evaluated this activity, and research examined its application in infections where this organism is known or suspected to be the cause. The evidence includes Subgroup Analyses from larger trials and extensive Microbiological Susceptibility Data that reported on patient experiences and how bacteria responded to the agent in laboratory settings.

---

Evidence for Use in Infections of the Brain, Abdomen, and Kidneys

For Bacterial Meningitis (infection of the membranes covering the brain and spinal cord), the research examined historical Comparative Trials where Zibac was studied in both adult and pediatric populations. Studies monitored the Clinical Response and examined the rate of Cerebrospinal Fluid (CSF) sterilization—meaning the monitored change in bacteria levels in the fluid surrounding the CNS.

For Complicated Intra-abdominal Infections (cIAI), research was conducted primarily through Randomized Controlled Trials (RCTs). This research often involved Zibac in combination with a separate medication that targets different types of bacteria. Therefore, comparative evidence for Zibac used as a single agent for cIAI is less characterized.

---

Areas of Research Uncertainty and Study Limitations

While the evidence for Zibac has been established for susceptible pathogens, certain research limitations and uncertainties are recognized in scientific literature. The core research structure for several key uses is historical, and comparative evidence against some of the newest classes of antibiotics is lacking. Follow-up durations were limited, meaning long-term effects are not fully established by the existing trial structure.

Common questions about Zibac (FAQ)

Q: What is the primary route of excretion for Zibac?

According to official regulatory documents, Zibac (Ceftazidime) is primarily eliminated from the body through the kidneys. A significant amount, approximately 80% to 90% of the administered drug, is excreted unchanged into the urine within the first 24 hours. This reliance on the kidneys for elimination is why prescribing information indicates the dose requires adjustment for people with reduced kidney function.

---

Q: Can Zibac be given orally?

No, Zibac is not given by mouth. Official product information states that the medicine is only intended for parenteral use, meaning it must be administered by a healthcare professional as an intravenous (IV) or intramuscular (IM) injection. Regulatory information notes that the drug is negligibly absorbed when taken by mouth.

---

Q: Does Zibac treat viral or fungal infections?

Zibac (Ceftazidime) is an antibiotic and a bactericidal agent, meaning it is specifically designed to target and kill bacteria. Official product information indicates that its mechanism of action works by inhibiting bacterial processes. Therefore, it is not indicated for or expected to treat illnesses caused by viruses or fungal infections.

How to Store and Dispose of Zibac (Ceftazidime)

The official storage conditions for Zibac (Ceftazidime), supplied as a sterile dry powder, vary significantly before and after reconstitution.

---

Storage Requirements

Product Form	Temperature and Protection
Dry Powder (Unreconstituted)	Store at Controlled Room Temperature (20 C to 25 C) and protect from light. Keep in the original container and out of the reach of children.
Reconstituted Solution	Use immediately. If necessary, it is typically stable for up to 12 hours at room temperature or up to 7 days when refrigerated (2 C to 8 C). Thawed solutions must not be refrozen.

---

Disposal

Any unused portion of the constituted solution and residue must be discarded. Disposal should be managed according to local regulations; the product should not be discharged into sewage systems or wastewater.